A Phase I Dose Escalation Study With Sunitinib (Sutent) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Sunitinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 02 Feb 2012 Planned end date changed from 1 Oct 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 25 Mar 2009 Status changed from not yet recruiting to recruiting
- 13 Nov 2008 New trial record.